Evidence map›Paper›PMID 40606528›Full record

ArticleGlobal health & medicine2025

Regional assessment is useful for identifying populations at high-risk of hepatitis B virus transmission: A nationwide analysis of population-based surveillance including the COVID-19 pandemic era.

Kazuya Okushin, Hideki Aizaki, Kazuhiko Ikeuchi, Toshiyuki Kishida, Akira Kado, Mitsuhiro Fujishiro, Takeya Tsutsumi, Tomoyuki Takura, Hiroshi Yotsuyanagi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Global health & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kazuya OkushinDepartment of Infection Control and Prevention, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hideki AizakiNational Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Kazuhiko IkeuchiDepartment of Infectious Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Toshiyuki KishidaDepartment of Infectious Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Akira KadoDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Mitsuhiro FujishiroDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Takeya TsutsumiDepartment of Infection Control and Prevention, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Tomoyuki TakuraDepartment of Healthcare Economics and Health Policy, The University of Tokyo, Tokyo, Japan.
Hiroshi YotsuyanagiDivision of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prevention of new infections is important for the elimination of viral hepatitis B. Assessing the impact of the Coronavirus disease 2019 (COVID-19) pandemic on hepatitis B incidence is important for future infection control measures. A recent hospital-based questionnaire survey implied that a regional assessment in each country would be useful for establishing new preventive measures. This retrospective study examined publicly reported national data of patients diagnosed with acute hepatitis B in Japan between 2015 and 2022. The transition of total numbers, incidence, sex, and age distribution in each year were analyzed. Comparisons were made between populous and non-populous prefectures before and during the COVID-19 pandemic (2015-2019

Indexed as

acute hepatitis BCOVID-19national dataregional assessmentsexually transmitted disease

Identifiers

PMID40606528
PMCPMC12209871

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.